

Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli *et al*

We read with great interest the article by Micheroli *et al*¹ for comparison of effectiveness between secukinumab (SEC) and tumour necrosis factor inhibitor (TNFi) in axial spondylitis (axSpA), with evidence conform to the current recommendation in a Swiss real-world setting.

According to current guidelines,^{2 3 4} interleukin-17 inhibitor (IL-17i) or alternative TNFi are both recommended as the switch option of biological disease-modifying antirheumatic drug in patients with previous TNFi failure. Although head-to-head comparison clinical trials between IL-17 inhibition and TNF blockade have been conducted in psoriatic arthritis recently^{5 6} and is ongoing in axSpA, we appreciated Micheroli *et al*¹ for their new information in this real-world indirect comparison study. However, some issues can be further discussed.

First, regarding the study design, it was not mentioned whether treatment adjustment was due to drug inefficacy or intolerability and the types of TNFi, receptor fusion protein or monoclonal antibody were unclear in the study. Since the administration time of SEC in the market was relatively short, subgroup analysis might be inconclusive due to underpowered sample size.



Second, there are huge difference in baseline clinical features between two groups. At baseline, patients in the SEC group had higher disease activity indexes including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), poorer physician and patient global assessments, higher C-reactive protein (CRP) as well as worse Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Metrology Index (BASMI), and even higher health-related index of EQ-5D:Euro-Qol-5 Dimension (EQ-5D), compared with those in the TNFi group. Although authors had done propensity score matching and multiple regression models to adjust this baseline incomparability, residual confounders existed, for example, comorbidities should be adjusted or stratified. This confounding by indication may explain the high infection rate in the SEC group. Physicians may tend to choose SEC in high infection risk patients.

Third, for effectiveness, the primary outcome in this study was drug retention rate at year 1. The secondary outcome was to assess the proportion of patients reaching 50% reduction in the BASDAI (BASDAI50) at 1 year. We agreed that drug retention rate is a good endpoint for composite effectiveness and safety. But we suggest that ASAS20, ASAS40 and ASDAS-CRP would be more suitable endpoints to be presented to compare with existing literatures. Furthermore, previous studies showing that ASAS20 and ASAS40 were both higher in patients treated with ixekizumab (IXE) in COAST-V⁷ study than in those in COAST-W⁸ study, implicating the superiority of IXE in patients with TNFi naive over TNFi failure. We suggest that authors should discuss on this inconsistency.

Fourth, for the safety aspects, 18.4% to 27.4% of patients discontinued treatment due to the adverse events. Other adverse events including headache, generalised peripheral pain and acne conglobata were much higher in the TNFi group than in the SEC group. These non-specific adverse events might attribute

to a wider and more potent proinflammatory effect of TNF than IL-17. Infection seemed to happen more frequently in patients treated with SEC. Among them, even one severe infection requiring hospitalisation occurred with unclear infection site and pathogen. Recurrence of breast cancer was identified in one patient treated with TNFi, which was considered possibly unrelated and inconclusive to the treatment from our point of view. For inflammatory bowel disease, conclusion was unfavourable and consistent with former randomised controlled trials (RCTs).⁹⁻¹¹ No uveitis developed in patients treated with SEC, which was inconsistent with former RCTs and required further investigation. Paradoxical psoriasis happened in two patients treated with SEC. It would be of great value to clarify the underlying mechanism for psoriasis pathogenesis despite IL-17i treatment.

Finally, for the reason of discontinuation, the percentage of ineffectiveness was comparable between TNFi and SEC (60.3% vs 58.1%), implying that over 50% of patients experienced unfavourable response to both drugs. We agree that there is still an unmet need for the treatment of the axSpA population. More therapeutic targets are required to improve the present status of treatment.

Jin-Xian Huang ,¹ Pui-Ying Leong,^{2,3} James Cheng-Chung Wei ^{2,3,4}

¹Department of Rheumatology, University of Hong Kong-Shenzhen Hospital, Shenzhen, China

²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

³Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

⁴Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan

Correspondence to Dr James Cheng-Chung Wei, Institute of Medicine, Chung Shan Medical University, Taichung 404, Taiwan; jccwei@gmail.com

Contributors JX-H conceived the idea and wrote the manuscript. PY-L and JCCW contributed to the critical review and revision of the manuscript. All authors approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Huang J-X, Leong P-Y, Wei J-C. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218779

Received 3 August 2020

Revised 7 August 2020

Accepted 8 August 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-218832>

Ann Rheum Dis 2020;**0**:1–2. doi:10.1136/annrheumdis-2020-218779

ORCID iDs

Jin-Xian Huang <http://orcid.org/0000-0001-5073-1205>

James Cheng-Chung Wei <http://orcid.org/0000-0003-0310-2769>

REFERENCES

- 1 Micheroli R, Tellenbach C, Scherer A, *et al*. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed

- to TNF inhibitors in the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2020;annrheumdis-2019-215934.
- 2 van der Heijde D, Ramiro S, Landewé R, *et al*. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* 2017;76:978–91.
 - 3 Tam LS, Wei JC-C, Aggarwal A, *et al*. 2018 APLAR axial spondyloarthritis treatment recommendations. *Int J Rheum Dis* 2019;22:340–56.
 - 4 Wei JC-C, Liu C-H, Tseng J-C, *et al*. Taiwan rheumatology association consensus recommendations for the management of axial spondyloarthritis. *Int J Rheum Dis* 2020;23:7–23.
 - 5 Smolen JS, Mease P, Tahir H, *et al*. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. *Ann Rheum Dis* 2020;annrheumdis-2020-217372.
 - 6 McInnes IB, Behrens F, Mease PJ, *et al*. Secukinumab versus adalimumab head-to-head comparison in biologic-naïve patients with active psoriatic arthritis through 52-weeks (EXCEED): a randomised, double-blind, phase-3b study. *Ann Rheum Dis* 2020;79:142–3.
 - 7 van der Heijde D, Cheng-Chung Wei J, Dougados M, *et al*. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet* 2018;392:2441–51.
 - 8 Deodhar A, Poddubnyy D, Pacheco-Tena C, *et al*. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a Phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. *Arthritis Rheumatol* 2019;71:599–611.
 - 9 Baeten D, Sieper J, Braun J, *et al*. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med* 2015;373:2534–48.
 - 10 Baeten D, Baraliakos X, Braun J, *et al*. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2013;382:1705–13.
 - 11 Pavelka K, Kivitz A, Dokoupilova E, *et al*. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, measure 3. *Arthritis Res Ther* 2017;19:285.